A new azole resistance mechanism in *Aspergillus fumigatus* consisting of a TR46/Y121F/T289A alteration in the cyp51A gene was recently described in the Netherlands. Strains containing these mutations are associated with invasive infection and therapy failure. This communication describes the first case of fatal invasive aspergillosis caused by TR46/Y121F/T289A outside the Netherlands, in the neighboring country of Belgium, suggesting geographical spread. TR46/Y121F/T289A leads to a recognisable phenotypic susceptibility pattern which should trigger cyp51A genotyping to monitor further spread.

**Case report**

A 57-year-old male, diagnosed with stage IIIA multiple myeloma (IgG kappa) in 2009, received a fully matched, unrelated haematopoietic stem cell transplantation following reduced-intensity conditioning (fludarabine-melphalan-ATG) in May 2012. Prior treatment regimens included multiple lines of chemotherapy, autologous transplantation, proteasome inhibitors (bortezomib), immunomodulatory agents (lenalidomide) and high-dose corticosteroids. At the time of transplantation, the patient had achieved a very good partial response (≥10% residual monoclonal paraprotein). The post-transplantation course was complicated by grade III hyperacute graft-versus-host disease (GVHD), involving mainly the skin and the gastro-intestinal tract. Methylprednisolone was started at 2 mg/kg and slowly tapered over the following weeks. However, high-dose corticotherapy needed to be re-installed in June 2012 because of a relapse of grade III acute GVHD. The patient was receiving fluconazole 400 mg daily since May 2012 as prophylaxis, but was never exposed to mold-active azoles.

One month later, in July 2012, the patient presented with dyspnea, pleuritic-type chest pain and fever, up to 39.9°C. Thoracic computed tomography (CT)-scan imaging showed multiple ill-defined lesions surrounded by ground glass opacities, suggestive of angio-invasive pulmonary mold infection. Serum galactomannan testing was repeatedly positive (maximum index 5.2; norm <0.5). Galactomannan detection in broncho-alveolar lavage (BAL) fluid tested positive as well (index 5.8), and *Aspergillus fumigatus* was cultured from BAL fluid. A diagnosis of probable pulmonary invasive aspergillosis (IA) was made following revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria [1]; the patient agreed to participate in a double-blinded phase III clinical trial comparing two azoles with anti-*Aspergillus* activity. However, serum galactomannan levels did not decrease while he received azole therapy and the clinical condition of the patient deteriorated rapidly.

Meanwhile, the isolate was tested for azole susceptibility, following Clinical and Laboratory Standards Institute (CLSI) protocols and showed an azole-resistant phenotype, with high-grade resistance to voriconazole (minimal inhibitory concentration (MIC) >16 mg/L) and less pronounced resistance to itraconazole (MIC =4 mg/L) and posaconazole (MIC =1 mg/L). Formal clinical breakpoints have not been established by CLSI for *Aspergillus* susceptibility testing. Based on the epidemiological cut-off values (wild-type distributions), resistance to itraconazole is defined as an MIC >1 mg/L, to voriconazole as ≥1 mg/L and to posaconazole as ≥0.5 mg/L [2]. An excellent essential agreement (EA) between CLSI and EUCAST methods was described in susceptibility testing of *A. fumigatus* to these azoles [3] and EUCAST already established breakpoints for itraconazole and posaconazole (itraconazole ≤1 mg/L is considered susceptible and ≥2 mg/L resistant; posaconazole ≤0.12 is considered susceptible and ≥0.25 resistant) [4]. A recent report, using an in vitro dynamic model of pulmonary IA that enabled simulation of human voriconazole pharmacokinetics, proposed CLSI breakpoints for voriconazole as ≤0.5 mg/L for susceptible and >1 mg/L for resistant [5].

Given this new finding of azole resistance and the rapid clinical decline, the investigators decided to withdraw the patient from the clinical study. Nine days after the start of azole therapy, liposomal amphotericin B was started at a dose of 3 mg/kg. Nevertheless, the patient
developed widespread IA with eye and brain involvement. A brain magnetic resonance imaging (MRI) scan taken 15 days after the initial diagnosis of invasive aspergillosis showed multiple nodular non-contrast-enhancing lesions suggestive of cerebral aspergillosis; this was confirmed by positive galactomannan testing in cerebrospinal fluid (index 4.8). The patient died 19 days after his first presentation with dyspnea. Azole resistance in the strain affecting the patient was shown to be due to cytochrome P450 51A mutation TR46/Y121F/T289A.

Characterisation of the *Aspergillus* isolate derived from the patient

The *Aspergillus* isolate, cultured from BAL fluid, was identified as *Aspergillus fumigatus* complex based on microscopic and macroscopic characteristics. This identification was confirmed to the species level with beta-tubulin sequencing, as described previously [6]. The isolate was tested for susceptibility with broth microdilution following the CLSI M38-A2 protocol [7]. Genotypic identification of the resistance mechanism was performed by sequencing of the cyp51A gene, as described previously [8].

Discussion and conclusion

Invasive aspergillosis is an important infectious complication in haematologic patients [9], but also in other groups of immunocompromised and intensive care patients [10]. Triazoles are the mainstay of therapy, with voriconazole the first-line therapy for IA [11]. However, reports of azole resistance have emerged, not only after long-term azole exposure [12], but also after short-term exposure and in azole-naive patients [13]. In the Netherlands, over 90% of the resistant clinical strains were attributable to the same resistance mechanism [13]. Therefore, an environmental route of resistance development is assumed and this is suspected to be related to the selective pressure of azole fungicides in the environment [14]. This predominant resistance mechanism is mediated by a tandem repeat of 34 bases (TR34) in the promoter region of the cyp51A gene and a substitution at position 98 (TR34/L98H), which encodes a residue of the azole target, sterol 14-alpha-demethylase. This resistance mechanism, conferring pan-azole resistance, has to date spread across Europe and even outside Europe [8,12,13,15-17]. The phenotype of the TR46/Y121F/T289A strains consists of a very high MIC to voriconazole (>16 mg/L), and an itraconazole MIC which is often multiple dilutions lower. In contrast, in TR34/L98H mutated strains, itraconazole MICs are typically higher than voriconazole MICs. This finding (MIC for voriconazole >16 mg/L and voriconazole MIC ≥MIC itraconazole) should raise awareness of this new TR46/Y121F/T289A resistance mechanism in other centres and countries.

Susceptibility testing should not delay initiation of therapy. Culture has a low sensitivity and takes about 48 h to become positive; susceptibility testing takes at least another 48 h. Resistance is therefore often a late finding in the management of the individual patient. Molecular techniques are a promising tool to rapidly provide information about resistance genotype, but clinicians should be aware that they are often designed to detect known resistance mechanisms and can therefore miss new mutations. On the other hand, not all mutations necessarily lead to a resistant phenotype [19]. Surveillance programs are crucial to monitor the local epidemiology of azole resistance, to correctly assess the risk of resistance associated with current treatment strategies. Susceptibility testing in individual patients with invasive aspergillosis should not be delayed until treatment failure because of the life-threatening character of this disease which is illustrated by this case.

Acknowledgments

EV receives a grant from Research Foundation Flandres (Fonds Wetenschappelijk Onderzoek Vlaanderen). An epidemiological study including typing and susceptibility testing of clinically relevant *Aspergillus* isolates has been approved by the local Ethics Committee University Hospitals Leuven, with reference S53024.

Conflicts of interest

Potential conflicts of interest are listed as follows. JM has served as consultant to Schering-Plough, Gilead Sciences, Merck, Sharp & Dohme, Pfizer Inc., Bio-Rad, Fujisawa healthcare, Inc., Astellas, Nextar and Zeneus (Cephalon). JM has received research funding from Bio-Rad, Merck, Sharp & Dohme, and Pfizer Inc. JM has been on the speaker’s bureau for Schering-Plough, Gilead Sciences, Merck, Sharp & Dohme, Pfizer Inc., Bio-Rad, Fujisawa healthcare, Inc, Astellas and Zeneus (Cephalon). KL has received research grants from Gilead Sciences, Pfizer Inc. and Merck, Sharp & Dohme and served on the speakers’ bureau of Pfizer Inc. and Merck, Sharp & Dohme. HS has served as consultant to Bristol Meyer Squibb.
References


